Analyst Expectations for ADC Therapeutics's Future
Portfolio Pulse from Benzinga Insights
ADC Therapeutics (NYSE:ADCT) has received 4 analyst ratings in the last quarter, with 2 bullish and 2 somewhat bullish, and none bearish. The average price target is $7.25, which is significantly higher than the current price of $0.6935, but this target represents a 22.29% decrease from the previous target of $9.33. Analysts rate stocks typically once a quarter based on various financial analyses and their ratings are opinions that should be considered as part of a broader investment strategy.
November 20, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADC Therapeutics has a positive outlook from analysts with an average price target of $7.25, suggesting a substantial upside from the current price, despite a decrease from the previous target.
The positive ratings from analysts, with no bearish outlooks, indicate a strong potential for stock price increase. However, the decrease in the average price target could temper expectations slightly. The confidence score is not at the maximum due to the inherent uncertainty in analyst predictions and market reactions.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100